Viridian Therapeutics, Inc.\DE financial data

Symbol
VRDN on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1377% % -27%
Debt-to-equity 12% % 22%
Return On Equity -53% % -16%
Return On Assets -47% % -14%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 95,442,008 shares 20%
Common Stock, Shares, Outstanding 82,229,158 shares 3.8%
Entity Public Float $731,800,000 USD -28%
Common Stock, Value, Issued $822,000 USD 3.8%
Weighted Average Number of Shares Outstanding, Basic 66,420,063 shares 52%
Weighted Average Number of Shares Outstanding, Diluted 66,420,063 shares 52%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $77,225,000 USD -1.6%
Operating Income (Loss) $328,117,000 USD -16%
Nonoperating Income (Expense) $26,146,000 USD 0.72%
Net Income (Loss) Attributable to Parent $301,971,000 USD -17%
Earnings Per Share, Basic -4 USD/shares 16%
Earnings Per Share, Diluted -4 USD/shares 16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments $490,900,000 USD -35%
Assets, Current $571,913,000 USD -25%
Property, Plant and Equipment, Net $1,125,000 USD -13%
Operating Lease, Right-of-Use Asset $2,582,000 USD 7.6%
Other Assets, Noncurrent $1,518,000 USD 78%
Assets $577,138,000 USD -25%
Accounts Payable, Current $10,063,000 USD 59%
Employee-related Liabilities, Current $10,714,000 USD 7%
Accrued Liabilities, Current $40,633,000 USD 17%
Contract with Customer, Liability, Current $372,000 USD 29%
Liabilities, Current $50,696,000 USD 23%
Contract with Customer, Liability, Noncurrent $140,000 USD -67%
Operating Lease, Liability, Noncurrent $2,200,000 USD 0%
Other Liabilities, Noncurrent $2,582,000 USD 19%
Liabilities $74,168,000 USD 15%
Accumulated Other Comprehensive Income (Loss), Net of Tax $363,000 USD -61%
Retained Earnings (Accumulated Deficit) $1,218,103,000 USD -33%
Stockholders' Equity Attributable to Parent $502,970,000 USD -29%
Liabilities and Equity $577,138,000 USD -25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $92,653,000 USD -105%
Net Cash Provided by (Used in) Financing Activities $9,212,000 USD -95%
Net Cash Provided by (Used in) Investing Activities $100,062,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 82,229,158 shares 3.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $16,621,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $169,647,000 USD -15%
Interest Paid, Excluding Capitalized Interest, Operating Activities $448,000 USD -0.88%
Deferred Tax Assets, Valuation Allowance $208,511,000 USD 34%
Deferred Tax Assets, Gross $208,511,000 USD 34%
Operating Lease, Liability $2,886,000 USD 4.9%
Payments to Acquire Property, Plant, and Equipment $86,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $302,540,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid $3,397,000 USD 1.3%
Property, Plant and Equipment, Gross $2,502,000 USD -8%
Operating Lease, Liability, Current $730,000 USD 24%
Lessee, Operating Lease, Liability, to be Paid, Year Two $836,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year One $965,000 USD 33%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $511,000 USD -15%
Lessee, Operating Lease, Liability, to be Paid, Year Three $854,000 USD 39%
Deferred Tax Assets, Operating Loss Carryforwards $77,430,000 USD 14%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $505,000 USD -19%
Additional Paid in Capital $1,531,003,000 USD 6.8%
Depreciation, Depletion and Amortization $117,000 USD -19%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $41,289,000 USD -30%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%